Similarly, our assessment of patients with IBD treated with anti-TNF and anti-IL-12/23 showed that S-specific Ab avidity plateaued after 3 vaccine doses, albeit the anti-TNF group did not reach the same level of avidity as the anti-IL-12/23–treated group. The gene discussed is TNF; the disease is inflammatory bowel disease.